Cabergoline Ratiopharm
Dopamine agonist for the treatment of hyperprolactinemia and prolactinomas
Quick Facts About Cabergoline Ratiopharm
Key Takeaways About Cabergoline Ratiopharm
- Effective prolactin reducer: Cabergoline normalizes prolactin levels in up to 90% of patients with hyperprolactinemia and can shrink prolactinomas significantly
- Convenient dosing: Unlike older dopamine agonists, cabergoline is taken only once or twice per week due to its long half-life of approximately 63–69 hours
- Better tolerated than bromocriptine: Clinical trials show that cabergoline causes fewer gastrointestinal side effects and is more effective at normalizing prolactin compared to bromocriptine
- Cardiac monitoring recommended: Echocardiography should be performed before starting and periodically during long-term treatment to monitor for valve fibrosis, although the risk is very low at standard hyperprolactinemia doses
- Pregnancy considerations: Treatment should generally be stopped when pregnancy is confirmed unless continued under specialist supervision
What Is Cabergoline Ratiopharm and What Is It Used For?
Cabergoline ratiopharm is a prescription dopamine agonist medication containing cabergoline 0.5 mg as the active ingredient. It is primarily used to treat hyperprolactinemia — a condition in which the pituitary gland produces excessive amounts of the hormone prolactin — and to suppress or inhibit lactation when medically indicated.
Cabergoline belongs to the ergot alkaloid family and works by selectively stimulating dopamine D2 receptors on the lactotroph cells of the anterior pituitary gland. In healthy physiology, dopamine acts as the primary inhibitor of prolactin secretion. When dopamine signaling is impaired or absent — as can occur with certain pituitary tumors — prolactin levels rise above normal, leading to a range of clinical symptoms.
Elevated prolactin levels (hyperprolactinemia) can manifest differently in men and women. In premenopausal women, common symptoms include irregular or absent menstrual periods (amenorrhea), unwanted breast milk production (galactorrhea), and infertility. In men, hyperprolactinemia can cause decreased libido, erectile dysfunction, and in rare cases, breast enlargement (gynecomastia). Both sexes may experience reduced bone mineral density over time if the condition is left untreated.
The most common cause of pathological hyperprolactinemia is a prolactinoma — a benign (non-cancerous) tumor of the pituitary gland that secretes excess prolactin. Prolactinomas are classified by size as microprolactinomas (less than 10 mm) or macroprolactinomas (10 mm or larger). Cabergoline is considered first-line medical therapy for both types, as endorsed by the Endocrine Society, the European Society of Endocrinology (ESE), and the Pituitary Society. Studies demonstrate that cabergoline normalizes prolactin levels in 83–92% of patients with microprolactinomas and achieves significant tumor shrinkage in approximately 80% of macroprolactinomas.
In addition to treating hyperprolactinemia, cabergoline ratiopharm may be prescribed for the suppression of established lactation when breastfeeding is contraindicated or when a woman chooses not to breastfeed. It is also used in certain clinical scenarios to inhibit the onset of lactation after stillbirth or neonatal loss. At higher doses (typically 3–6 mg per day, far exceeding doses for hyperprolactinemia), cabergoline has been used off-label as adjunctive therapy in Parkinson's disease, though this indication carries a higher risk of cardiac valve complications.
Both medications are dopamine agonists, but cabergoline offers several advantages: a much longer half-life (63–69 hours vs. 6–8 hours), allowing weekly rather than daily dosing; higher efficacy in normalizing prolactin (83–92% vs. 60–80%); and better tolerability with fewer gastrointestinal side effects. A landmark randomized controlled trial published in the New England Journal of Medicine (Webster et al., 1994) established cabergoline's superiority over bromocriptine for hyperprolactinemia treatment.
What Should You Know Before Taking Cabergoline Ratiopharm?
Before starting cabergoline, your doctor should assess your cardiac valve function, liver function, and medical history. Cabergoline is contraindicated in patients with a history of cardiac valvular disorders, pulmonary or retroperitoneal fibrotic reactions, and severe hepatic impairment.
Contraindications
Cabergoline ratiopharm must not be used in the following situations:
- Hypersensitivity to cabergoline, any other ergot alkaloid, or any of the excipients in the formulation
- History of cardiac valvular disorders as confirmed by echocardiography, including valvular thickening, restriction, or stenosis/regurgitation
- History of pulmonary, pericardial, or retroperitoneal fibrotic disorders
- Severe hepatic impairment — cabergoline is extensively metabolized by the liver, and impaired hepatic function can lead to dangerously elevated drug levels
- Pre-eclampsia, eclampsia, or postpartum hypertension — cabergoline should not be used for lactation suppression in women with hypertensive disorders of pregnancy
- Long-term treatment in patients with anatomical evidence of cardiac valve disease on echocardiography
Warnings and Precautions
Several important precautions apply when taking cabergoline ratiopharm. Your doctor will evaluate these carefully before prescribing the medication and will monitor you throughout treatment.
Cardiac valve fibrosis: Long-term use of ergot-derived dopamine agonists, including cabergoline, has been associated with fibrotic changes in cardiac valves. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) recommend echocardiographic assessment before treatment initiation, within 3–6 months after starting, and then at regular intervals (typically every 6–12 months). The risk is dose-dependent, and studies suggest that at the low doses used for hyperprolactinemia (typically 0.5–2 mg per week), clinically significant valvulopathy is rare. Nevertheless, monitoring remains essential.
Orthostatic hypotension: Cabergoline can cause a significant drop in blood pressure upon standing, particularly during the first few days of treatment. Patients should rise slowly from sitting or lying positions. This effect is most pronounced during dose initiation and upward titration.
Impulse control disorders: Like other dopamine agonists, cabergoline has been associated with pathological gambling, hypersexuality, compulsive spending, and binge eating. These behaviors are typically reversible upon dose reduction or discontinuation. Patients and their families should be advised to monitor for these symptoms.
Somnolence and sudden sleep onset: Dopamine agonists, including cabergoline, may cause excessive daytime sleepiness or sudden sleep episodes. Patients should be cautioned about driving or operating heavy machinery, particularly at the start of treatment or after dose increases.
Hepatic impairment: Patients with moderate hepatic impairment should receive lower doses and be monitored closely. Cabergoline is contraindicated in severe hepatic impairment.
In rare cases, cabergoline has been associated with pleural effusion, pleural fibrosis, pulmonary fibrosis, pericarditis, pericardial effusion, and retroperitoneal fibrosis. Patients who develop persistent cough, chest pain, shortness of breath, flank pain, or leg swelling should seek medical attention promptly. Erythrocyte sedimentation rate (ESR) and serum creatinine should be measured at baseline and periodically monitored.
Pregnancy and Breastfeeding
The use of cabergoline during pregnancy requires careful consideration. Current guidelines from the Endocrine Society recommend discontinuing cabergoline once pregnancy is confirmed, unless the patient has a macroprolactinoma with a high risk of tumor growth during pregnancy. In such cases, continued treatment under close specialist supervision may be warranted.
Observational data from registries tracking over 1,000 pregnancies exposed to cabergoline in the first trimester have not demonstrated a significant increase in the rate of congenital malformations, spontaneous abortions, or preterm births compared to the general population. However, the data remain insufficient to definitively rule out all risks, and prospective controlled studies are lacking.
Women of childbearing potential should use effective contraception during treatment and should undergo pregnancy testing if menstruation is delayed. Mechanical contraception is preferred over hormonal methods during cabergoline therapy, as hormonal contraceptives may interact with prolactin physiology.
Since cabergoline suppresses lactation, it should not be used by women who intend to breastfeed. The drug passes into breast milk in small amounts, and its effects on the nursing infant have not been fully studied.
How Does Cabergoline Ratiopharm Interact with Other Drugs?
Cabergoline interacts primarily with dopamine antagonists (which can reduce its effectiveness), other ergot alkaloids (which increase the risk of vasoconstriction and fibrosis), and certain macrolide antibiotics (which can increase cabergoline blood levels). Always inform your doctor about all medications you are taking.
Drug interactions with cabergoline can be broadly categorized into pharmacodynamic interactions (where another drug opposes or enhances cabergoline's effects) and pharmacokinetic interactions (where another drug alters the absorption, distribution, metabolism, or excretion of cabergoline). Understanding these interactions is critical for safe and effective treatment.
Cabergoline works by activating dopamine D2 receptors. Any medication that blocks these receptors will directly counteract cabergoline's therapeutic effect, potentially leading to treatment failure and rising prolactin levels. The most clinically important examples include antipsychotic medications (both typical and atypical), as well as antiemetic drugs that work through dopamine blockade.
Since cabergoline is an ergot derivative, concurrent use with other ergot alkaloids can increase the risk of peripheral vasoconstriction, vasospasm, and fibrotic complications. This combination should be avoided. Similarly, cabergoline is metabolized by cytochrome P450 3A4 (CYP3A4), and potent inhibitors of this enzyme can increase cabergoline plasma concentrations.
| Drug / Class | Interaction Type | Clinical Effect | Recommendation |
|---|---|---|---|
| Metoclopramide | Pharmacodynamic — Major | Blocks D2 receptors, directly opposes cabergoline's prolactin-lowering effect | Avoid combination; use ondansetron for nausea instead |
| Domperidone | Pharmacodynamic — Major | D2 antagonist that counteracts prolactin suppression | Avoid combination |
| Antipsychotics (haloperidol, risperidone, olanzapine, chlorpromazine) | Pharmacodynamic — Major | D2 blockade abolishes cabergoline efficacy; antipsychotic-induced hyperprolactinemia | Avoid if possible; if essential, consider aripiprazole (partial D2 agonist) as alternative |
| Ergot alkaloids (ergotamine, dihydroergotamine) | Pharmacodynamic — Major | Additive risk of vasoconstriction, vasospasm, and fibrotic disorders | Contraindicated during long-term cabergoline use |
| Macrolide antibiotics (erythromycin, clarithromycin) | Pharmacokinetic — Moderate | CYP3A4 inhibition may increase cabergoline plasma levels | Monitor for increased side effects; consider azithromycin (weaker CYP3A4 inhibitor) |
| Antihypertensives | Pharmacodynamic — Minor | Additive hypotensive effect, especially orthostatic hypotension | Monitor blood pressure; adjust antihypertensive dose if needed |
Major Interactions
The most clinically significant interactions are with dopamine antagonists. These drugs directly oppose the mechanism of action of cabergoline, rendering it ineffective at reducing prolactin levels. If a patient requires both an antipsychotic and treatment for hyperprolactinemia, the endocrinologist and psychiatrist should collaborate closely. In some cases, aripiprazole — a partial dopamine agonist — may be considered as an antipsychotic alternative that is less likely to elevate prolactin.
Concurrent use of other ergot derivatives is contraindicated during long-term cabergoline therapy due to the cumulative risk of fibrotic complications affecting cardiac valves, the retroperitoneum, and the lungs. Patients using triptans (e.g., sumatriptan) for migraines should discuss this with their doctor, though triptans are serotonin agonists rather than ergot alkaloids and the interaction risk is generally lower.
Minor Interactions
Alcohol may potentiate the orthostatic hypotension and dizziness caused by cabergoline, particularly during the initial weeks of therapy. Patients should be advised to limit alcohol consumption. Additionally, some patients report increased sensitivity to the sedating effects of antihistamines and benzodiazepines when taking cabergoline, although formal pharmacokinetic studies have not confirmed significant interactions with these drug classes.
What Is the Correct Dosage of Cabergoline Ratiopharm?
The typical starting dose of cabergoline for hyperprolactinemia is 0.25 mg (half a tablet) twice weekly or 0.5 mg once weekly. The dose is then gradually titrated upward based on prolactin levels, usually increasing by 0.25–0.5 mg per month until an effective maintenance dose is reached.
Dosing of cabergoline ratiopharm is individualized based on the indication, prolactin response, and tolerability. The scored 0.5 mg tablet can be halved to allow flexible dose titration. It is important to note that cabergoline is dosed on a weekly basis, not daily — a distinction that must be clearly understood to avoid accidental overdosing.
Adults — Hyperprolactinemia
Hyperprolactinemia (Standard Protocol)
Starting dose: 0.25 mg twice weekly or 0.5 mg once weekly, taken with food to reduce nausea.
Titration: Increase by 0.25–0.5 mg at monthly intervals based on serum prolactin measurement. Most patients respond to 0.5–1.0 mg per week.
Maximum dose: Up to 4.5 mg per week has been used in clinical trials, though doses above 2 mg per week are uncommon for hyperprolactinemia.
Maintenance: Once prolactin is normalized, the dose can often be reduced. Some patients achieve sustained remission and can discontinue treatment after 2–3 years of prolactin normalization.
Lactation Suppression (Single Indication)
Prevention of lactation onset: 1 mg (two tablets) given as a single dose on the first day postpartum.
Suppression of established lactation: 0.25 mg every 12 hours for 2 days (total dose: 1 mg).
| Indication | Starting Dose | Usual Maintenance | Maximum Dose |
|---|---|---|---|
| Hyperprolactinemia | 0.25 mg twice/week or 0.5 mg once/week | 0.5–2 mg/week | 4.5 mg/week |
| Inhibition of lactation | 1 mg single dose (day 1 postpartum) | N/A (single dose) | 1 mg total |
| Suppression of established lactation | 0.25 mg every 12h for 2 days | N/A (short course) | 1 mg total |
Children
The safety and efficacy of cabergoline in children and adolescents under 16 years of age have not been established in controlled clinical trials. However, in pediatric endocrinology practice, cabergoline is sometimes used off-label for prolactinomas in adolescents, typically following the same dose titration principles used for adults. Published case series suggest comparable efficacy and tolerability in this age group, but treatment should only be initiated by an experienced pediatric endocrinologist.
Elderly Patients
Clinical experience with cabergoline in elderly patients (over 65 years) is limited. No specific dose adjustment is required based on age alone, but elderly patients may be more susceptible to orthostatic hypotension and should have their blood pressure monitored more frequently during treatment initiation. Co-morbidities and concurrent medications should be carefully reviewed, as the risk of drug interactions may be higher in this population.
Missed Dose
If you miss a scheduled dose, take it as soon as you remember, provided the next dose is not due within 2–3 days. If it is close to the time of your next scheduled dose, skip the missed dose and resume your normal dosing schedule. Do not take a double dose to make up for a missed one. If you frequently forget doses, consider setting a weekly alarm or keeping a medication diary to help maintain consistency.
Overdose
Symptoms of cabergoline overdose may include severe nausea, vomiting, orthostatic hypotension, abdominal cramps, hallucinations, and confusion. In cases of significant overdose, treatment is supportive: maintain blood pressure, monitor cardiac rhythm, and administer activated charcoal if the ingestion was recent. There is no specific antidote for cabergoline. Patients should be monitored for several days given the drug's long half-life. Contact your local poison control center or emergency services immediately if an overdose is suspected.
What Are the Side Effects of Cabergoline Ratiopharm?
The most common side effects of cabergoline include nausea (reported in approximately 25–30% of patients), headache, dizziness, and fatigue. Most side effects are dose-dependent, mild in severity, and tend to improve within the first few weeks of treatment. Serious side effects such as cardiac valve fibrosis are rare at standard doses.
Like all medications, cabergoline ratiopharm can cause side effects, although not everybody gets them. The frequency and severity of side effects are generally dose-related — higher doses used for Parkinson's disease carry a greater risk than the lower doses used for hyperprolactinemia. Taking cabergoline with food and starting at a low dose with gradual titration helps minimize gastrointestinal side effects.
The following classification is based on data from clinical trials and post-marketing surveillance as reported in the European Medicines Agency's (EMA) Summary of Product Characteristics (SmPC) and the FDA prescribing information:
Very Common (affects more than 1 in 10 patients)
- Nausea
- Headache
- Dizziness / vertigo
Common (affects 1 to 10 in 100 patients)
- Constipation
- Abdominal pain / dyspepsia
- Fatigue / asthenia
- Orthostatic hypotension (low blood pressure when standing)
- Hot flushes
- Depression
- Breast pain
- Vomiting
- Drowsiness / somnolence
Uncommon (affects 1 to 10 in 1,000 patients)
- Peripheral edema (swollen ankles/feet)
- Palpitations
- Nasal congestion
- Insomnia
- Paresthesia (tingling, numbness)
- Visual disturbances
- Raynaud's phenomenon (cold, pale fingers)
- Impulse control disorders (pathological gambling, hypersexuality)
Rare (affects fewer than 1 in 1,000 patients)
- Cardiac valve fibrosis / valvulopathy
- Pleural fibrosis / pleural effusion
- Retroperitoneal fibrosis
- Pericardial effusion / pericarditis
- Sudden sleep onset episodes
- Psychotic reactions (hallucinations, delusions)
- Hepatic dysfunction / elevated liver enzymes
- Digital vasospasm
If you experience any side effects that concern you, contact your prescribing physician. Some side effects — such as nausea and dizziness — typically diminish over time as your body adjusts to the medication. However, if you develop unexplained shortness of breath, persistent cough, chest pain, or leg edema, seek medical attention promptly, as these may indicate fibrotic complications.
Nausea: Take cabergoline with food or at bedtime. Starting with a low dose (0.25 mg) and titrating slowly helps the body adjust. Dizziness: Rise slowly from sitting or lying positions, especially during the first week. Fatigue: Take the dose in the evening, as drowsiness tends to peak 2–4 hours after ingestion.
How Should You Store Cabergoline Ratiopharm?
Store cabergoline ratiopharm tablets at room temperature (below 25°C / 77°F) in the original packaging to protect from moisture and light. Keep out of the reach and sight of children.
Proper storage is essential to maintain the potency and safety of cabergoline tablets throughout their shelf life. Exposure to excessive heat, humidity, or direct sunlight can degrade the active ingredient and reduce the medication's effectiveness.
Store the tablets in a dry place at a temperature not exceeding 25°C (77°F). Do not freeze. Keep the tablets in the original blister packaging until use to protect them from moisture. Do not transfer tablets to other containers unless they provide equivalent protection from light and humidity.
Check the expiry date printed on the outer carton and blister strips. Do not use cabergoline after the expiry date (stated as "EXP" followed by the month and year). The expiry date refers to the last day of that month. If the tablets appear discolored, crumbled, or have an unusual odor, do not use them.
Dispose of expired or unused tablets through a pharmacy take-back program or follow your local waste disposal regulations. Do not flush medicines down the toilet or throw them in household waste, as this may contaminate the environment.
What Does Cabergoline Ratiopharm Contain?
Each tablet contains 0.5 mg of cabergoline as the active substance, along with inactive ingredients (excipients) including lactose and leucine. The tablets are white to off-white, flat, oval-shaped, and scored on one side for easy splitting.
The active substance in Cabergoline ratiopharm is cabergoline, a synthetic ergoline compound with a molecular formula of C26H37N5O2 and a molecular weight of approximately 451.6 g/mol. Each tablet contains precisely 0.5 mg of cabergoline.
The inactive ingredients (excipients) serve various pharmaceutical purposes such as providing bulk, aiding tablet formation, ensuring stability, and facilitating dissolution. Typical excipients in cabergoline tablets may include:
- Lactose (anhydrous): Functions as a filler/diluent. Patients with rare hereditary galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should consult their doctor before taking this medicine
- Leucine (L-leucine): Acts as a lubricant during tablet manufacturing
The tablets are white to slightly yellowish-white, flat, oblong, and scored on one side. The score line allows the tablet to be divided into two equal halves of 0.25 mg each, which is particularly useful during initial dose titration or for patients who require lower doses.
Cabergoline ratiopharm is manufactured by Ratiopharm, a subsidiary of Teva Pharmaceutical Industries — one of the world's largest generic pharmaceutical companies. The product meets the same pharmacopoeia standards and bioequivalence requirements as the originator brand, ensuring therapeutic equivalence.
Frequently Asked Questions About Cabergoline Ratiopharm
Cabergoline is primarily used to treat hyperprolactinemia — a condition where the pituitary gland produces too much prolactin. It is prescribed for conditions including prolactin-secreting pituitary adenomas (prolactinomas), idiopathic hyperprolactinemia, and to suppress lactation when medically necessary. Cabergoline works by stimulating dopamine D2 receptors in the pituitary gland, which inhibits prolactin production. It may also be used off-label for Parkinson's disease at higher doses.
Cabergoline begins to lower prolactin levels within 3 hours of taking the first dose. However, noticeable clinical improvement typically takes 2–4 weeks. Prolactin levels may normalize within the first month of treatment. Regular blood tests are used to monitor prolactin levels and adjust the dose accordingly. For women with hyperprolactinemia-related menstrual irregularities, restoration of normal menstrual cycles may take 1–3 months.
The most common side effects include nausea (25–30%), headache, dizziness, and fatigue. Some patients may experience constipation, abdominal pain, or low blood pressure (especially when standing up). These side effects are usually mild and tend to improve as your body adjusts to the medication over 1–2 weeks. Taking cabergoline with food and at bedtime can help reduce nausea and dizziness.
Cabergoline should generally be discontinued when pregnancy is confirmed, unless continued treatment is medically necessary under specialist supervision (e.g., for large macroprolactinomas at risk of expansion). Observational data from over 1,000 pregnancies have not shown a significant increase in birth defects, but the evidence remains limited. Women planning pregnancy should discuss a discontinuation plan with their endocrinologist before conception, and pregnancy testing is recommended whenever a menstrual period is missed.
At the low doses used for hyperprolactinemia (typically 0.25–2 mg per week), the risk of cardiac valve fibrosis is very low. However, echocardiographic monitoring is recommended before starting treatment and periodically during long-term use, especially at higher doses. The risk is dose-dependent and primarily associated with the higher doses used in Parkinson's disease treatment (3–6 mg/day). Your doctor will arrange regular echocardiograms as part of your monitoring plan.
Cabergoline has a long half-life of approximately 63–69 hours, so it is typically taken once or twice per week — not daily. The usual starting dose is 0.25 mg (half a tablet) twice weekly, or 0.5 mg once weekly. Your doctor will adjust the dose based on your prolactin blood levels and clinical response. It is important to take the medication on the same day(s) each week to maintain consistent drug levels.
References
- Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-288. doi:10.1210/jc.2010-1692
- Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med. 1994;331(14):904-909. doi:10.1056/NEJM199410063311403
- Colao A, Di Sarno A, Guerra E, et al. Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women. Nat Clin Pract Endocrinol Metab. 2006;2(4):200-210. doi:10.1038/ncpendmet0160
- European Medicines Agency (EMA). Summary of Product Characteristics: Cabergoline. Available at: www.ema.europa.eu
- Auriemma RS, Pivonello R, Ferreri L, et al. Cabergoline use for pituitary tumors and valvular disorders. Endocrinol Metab Clin North Am. 2015;44(1):89-97. doi:10.1016/j.ecl.2014.10.007
- Dekkers OM, Lagro J, Burman P, et al. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(1):43-51. doi:10.1210/jc.2009-1045
- Molitch ME. Pharmacologic resistance in prolactinoma patients. Pituitary. 2005;8(1):43-52. doi:10.1007/s11102-005-5085-2
- World Health Organization (WHO). WHO Model List of Essential Medicines. 23rd edition, 2023.
- British National Formulary (BNF). Cabergoline: Indications, dose, contra-indications, side-effects. Available at: bnf.nice.org.uk
- Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007;356(1):29-38. doi:10.1056/NEJMoa062222
Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians in endocrinology, pharmacology, and internal medicine. All medical content follows the GRADE evidence framework and adheres to guidelines from the Endocrine Society, the European Medicines Agency (EMA), the FDA, and the World Health Organization (WHO).
Written by medical specialists with expertise in endocrinology and pharmacology
Reviewed by the iMedic Medical Review Board for clinical accuracy
Level 1A — Based on systematic reviews and meta-analyses of RCTs
No commercial funding. No pharmaceutical industry sponsorship